We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases Guidances On Trial Designs for Rhinitis, Anthrax Drugs
FDA Releases Guidances On Trial Designs for Rhinitis, Anthrax Drugs
The FDA is providing additional information on trial designs for sponsors developing therapies to treat allergic and nonallergic rhinitis and anthrax exposure.